---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-027059"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:27:39.283951+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA Fast Track for NRX-100 in suicidal depression; ANDA filing deficiency noted

## Summary
- FDA Fast Track designation for NRX-100 (IV ketamine) to treat suicidal ideation in depression, including bipolar depression.
- Addressable population expands to 13M Americans considering suicide/year, 10x larger than prior 2017 designation.
- Company also received FDA letter on August 13 citing missing batch records and 6% inactive ingredient difference in ANDA for NRX-100; expects to remedy and resubmit.
- Fast Track enables potential CNPV/accelerated approval, rolling review, and enhanced FDA communication.
- NRX-100 is preservative-free ketamine; company citizen petition to remove BZT from IV ketamine products.

## SEC filing metadata
- accession: 0001437749-25-027059
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925027059/0001437749-25-027059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925027059/nrxp20250814_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-027059
- JSON: https://secwatch.observer/filing/0001437749-25-027059.json
- Plain text: https://secwatch.observer/filing/0001437749-25-027059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.